Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia
Ruth Namazzi, Robert O. Opoka, Charles Ssuuna, Michael J. Goings, Kathryn McElhinney, Dibyadyuti Datta, Russell E. Ware, Chandy C. John, Andrea L. Conroy · 2026
Read Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia by Ruth Namazzi, Robert O. Opoka, Charles Ssuuna, Michael J. Goings, Kathryn McElhinney, Dibyadyuti Datta, Russell E. Ware, Chandy C. John, Andrea L. Conroy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13523223.txt.
Description
Ruth Namazzi and colleagues show that a sickle cell drug distorts a bedside kidney test in Ugandan children in a 2026 analysis nested in a clinical trial. Two hundred forty-eight children with sickle cell anemia had creatinine, a kidney marker, measured by a point-of-care device and by a reference laboratory method. About half started hydroxyurea during a year of follow-up as part of routine care.
At enrollment the two methods agreed well. At follow-up, children on hydroxyurea showed device readings notably higher than laboratory values, with some results crossing into the abnormal range, while untreated children showed no such gap. Drug levels in blood explained most of the variation in device readings. The authors warn that the interference can misclassify kidney function and mislead care decisions.
Catalog record
| CREATOR | Ruth Namazzi, Robert O. Opoka, Charles Ssuuna, Michael J. Goings, Kathryn McElhinney, Dibyadyuti Datta, Russell E. Ware, Chandy C. John, Andrea L. Conroy |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20743 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |